Health

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/11/2026, 08:21:27 UTC.

Briefings

ProMis Neurosciences shares dropped sharply after Acumen Pharmaceuticals failed to show cognitive improvement in its Alzheimer's drug. CEO Neil Warma dismissed investor concerns as an overreaction, though the market reaction remains a key outcome. The study compared Acumen's drug to a placebo in a mid-stage trial.

Key points

• ProMis Neurosciences shares fell sharply following Acumen Pharmaceuticals' failure of its Alzheimer's drug in a mid-stage study.
• CEO Neil Warma stated the market reaction was an overreaction and not justified.

Context

ProMis Neurosciences develops amyloid-targeting treatments for Alzheimer's disease. Acumen Pharmaceuticals developed a similar mechanism drug that failed in a mid-stage study, causing ProMis shares to drop. CEO Neil Warma commented on investor assumptions.

Limitations

Evidence is limited to a single news snippet from Adam's Biotech Scorecard newsletter. No specific dates, patient numbers, or study outcomes beyond 'mid-stage' are provided. No causal link between Acumen's failure and ProMis's stock price is confirmed, only a reported reaction.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/11/2026, 22:43:44 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihdlez4bobfe3plkvcvitrzaofzftbyqtkdwdyoeoyo5smcggidjq